Triptolide Inhibits the Proliferation of Immortalized HT22 Hippocampal Cells Via Persistent Activation of Extracellular Signal-Regulated Kinase-1/2 by Down-Regulating Mitogen-Activated Protein Kinase Phosphatase-1 Expression

Hee Sang Koo, M.D.,¹ Sung Don Kang, M.D.,¹ Ju Hwan Lee, M.D.,² Nam-Ho Kim, M.D.,² Hun-Taeg Chung, M.D., Ph.D.,³ Hyun-Ok Pae, M.D., Ph.D.⁴

Departments of Neurosurgery,¹ Anesthesiology and Pain Medicine,² Department of Microbiology and Immunology,³ Wonkwang University School of Medicine, Iksan, Korea
Department of Cardiovascular Medicine,² Wonkwang University Hospital, Iksan, Korea
Department of Biological Science,⁴ University of Ulsan College of Medicine, Ulsan, Korea

Objective: Triptolide (TP) has been reported to suppress the expression of mitogen-activated protein kinase (MAPK) phosphatase-1 (MKP-1), of which main function is to inactivate the extracellular signal-regulated kinase-1/2 (ERK-1/2), the p38 MAPK and the c-Jun N-terminal kinase-1/2 (JNK-1/2), and to exert antiproliferative and pro-apoptotic activities. However, the mechanisms underlying antiproliferative and pro-apoptotic activities of TP are not fully understood. The purpose of this study was to examine whether the down-regulation of MKP-1 expression by TP would account for antiproliferative activity of TP in immortalized HT22 hippocampal cells.

Methods: MKP-1 expression and MAPK phosphorylation were analyzed by Western blot. Cell proliferation was assessed by ³H-thymidine incorporation. Small interfering RNA (siRNA) against MKP-1, vanadate (a phosphatase inhibitor), U0126 (a specific inhibitor for ERK-1/2), SB203580 (a specific inhibitor for p38 MAPK), and SP600125 (a specific inhibitor for JNK-1/2) were employed to evaluate a possible mechanism of antiproliferative action of TP.

Results: At its non-cytotoxic dose, TP suppressed MKP-1 expression, reduced cell growth, and induced persistent ERK-1/2 activation. Similar growth inhibition and ERK-1/2 activation were observed when MKP-1 expression was blocked by MKP-1 siRNA and its activity was inhibited by vanadate. The antiproliferative effects of TP, MKP-1 siRNA, and vanadate were significantly abolished by U0126, but not by SB203580 or SP600125.

Conclusion: Our findings suggest that TP inhibits the growth of immortalized HT22 hippocampal cells via persistent ERK-1/2 activation by suppressing MKP-1 expression. Additionally, this study provides evidence supporting that MKP-1 may play an important role in regulation of neuronal cell growth.

KEY WORDS: Triptolide - HT22 hippocampal cell - Mitogen-activated protein kinase phosphatase-1 - Extracellular signal-regulated kinase-1/2 - Mitogen-activated protein kinase - Proliferation.

INTRODUCTION

The mitogen-activated protein kinase (MAPK) family, including the extracellular signal-regulated kinase-1/2 (ERK-1/2), the c-Jun N-terminal kinase-1/2 (JNK-1/2), and the p38 MAPK, is involved in the survival, proliferation and differentiation of neuronal cells. Some of the MAPKs appropriately regulate cellular proliferation, and others promote the differentiation towards the neuron lineage. The MAPKs are also involved in survival and apoptosis of neuronal cells. The MAPK pathway is activated through a cascade of sequential phosphorylation...
events, and dephosphorylation of MAPKs mediated by phosphatases represents a highly efficient mode of kinase deactivation. A number of protein phosphatases are known to deactivate MAPKs, including tyrosine, serine/threonine, and dual-specificity phosphatases. In mammalian cells, the dual-specificity protein phosphatases, which are often referred to as MAPK phosphatases (MKPs), are the primary phosphatases responsible for dephosphorylation/deactivation of MAPKs. To date, at least 10 MKPs have been identified in mammalian cells, with MKP-1 being the archetype. Although MKP-1 was initially thought to be a phosphatase specific for the ERK-1/2, recent studies demonstrated that MKP-1 also efficiently inactivated JNK-1/2 and p38 MAPK.

Triptolide (TP) is the active component of the Chinese herb Tripterygium wilfordii Hook F, which has been used for thousands of years as a therapeutic agent against various inflammatory diseases. Recently, accumulating evidence demonstrates that besides its anti-inflammatory activity, TP also possesses antiproliferative and pro-apoptotic activities in various tumors and immortalized cells. However, the cellular and molecular mechanisms underlying antiproliferative and pro-apoptotic activities of TP are not fully understood.

TP has been screened originally as a potent inhibitor that can block the expression of MKP-1 and widely used for understanding the relationship between MKP-1 expression and MAPK inactivation, which raises a question regarding whether the down-regulation of MKP-1 expression by TP would account for at least one of its biological activities. Because MKP-1 down-regulates MAPK activation that plays important roles in proliferation and apoptosis, we have hypothesized that the down-regulation of MKP-1 expression by TP would account for its antiproliferative and/or pro-apoptotic activities in immortalized HT22 hippocampal cells. Here, we have demonstrated that TP at a non-cytotoxic dose potently inhibits the proliferation of HT22 cells through its inhibition of MKP-1 expression.

MATERIALS AND METHODS

Materials

Dulbecco’s-modified Eagle’s medium (DMEM), TP, paclitaxel, 4’, 6-diamidine-2-phenylindole (DAPI), Trypan blue solution, sodium dodecyl sulfate (SDS), rhodamine 6G, a lactate dehydrogenase (LDH) assay kit, and sodium orthovanadate (NaVO₄) were purchased from Sigma Aldrich (St. Louis, MO, USA). U0126, SB203580 and SP600125 were obtained from Calbiochem (San Diego, CA, USA). The antibodies for anti-p38 MAPK, anti-phospho-p38 MAPK (P-p38), anti-ERK-1/2, anti-phospho-ERK-1/2 (P-ERK-1/2), anti-JNK-1/2, anti-phospho-JNK-1/2 (P-JNK-1/2), anti-MKP-1, anti-phospho-MKP-1 (P-MKP-1), and anti-β-actin, and the small interfering RNA (siRNA) against mouse MKP-1 were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Antibody for horseradish peroxidase-conjugated anti-IgG antibody was obtained from Sigma Aldrich. The enhanced chemiluminescence (ECL) solution was purchased from Lifesciences (Piscataway, NJ, USA). The mouse MKP-1 expression plasmid, pSG5-MKP-1 containing a single copy of the Myc epitope tag, was kindly provided by K. T. Kim (Pohang University of Science and Technology, Pohang, Korea). All other chemicals used were of the highest grade available commercially.

Cell culture and transfection

The hippocampal cell line (HT22 cells) used in this study is a sub-line cloned from the parent HT4 cells that were immortalized from primary mouse hippocampal neurons using a temperature-sensitive small virus-40 T antigen. HT22 cells were cultured in DMEM supplemented with 10% fetal bovine serum (FBS) and 50 μg/mL gentamicin, 0.05 unit/mL penicillin, 50 μg/mL streptomycin, pH 7.4 at 37 °C in an atmosphere of 95% air and 5% CO₂. In a 6-well tissue culture plate, HT22 cells were seeded at a density of about 2 × 10⁵ cells per well. When the density of cells reached 50-60%, cells were transfected with pSG5-MKP-1 or MKP-1 siRNA, using Lipofectamine™, reagent (Invitrogen Life Technologies, Carlsbad, CA, USA) according to the manufacturer’s instruction. After incubation for 24 h, the transfected cells were treated as indicated for analysis.

Assessment of cell viability and apoptosis

Cell viability was determined by Trypan blue dye-exclusion assay. HT22 cells were collected at an indicated time and incubated with 0.4% Trypan blue, observed under a microscope, and the stained and unstained cells were then counted on a hemocytometer separately. Cell viability was calculated according to the following formula: cell viability (%) = (unstained cells number/total cells number) × 100. Cell death was calculated by the following formula: cell death (%) = (stained cells number/total cells number) × 100. To assess apoptosis, the nuclei of HT22 cells were stained with DAPI, as previously reported. Cells were fixed in phosphate buffered saline (PBS) containing 3.7% paraformaldehyde for 15 min. After fixation, cells were washed twice with PBS and then stained with DAPI. After three washes, cells were observed under fluorescence microscope.
Western Blot Analysis

Cells were treated with TP, scraped and collected in 1 x PBS and then centrifuged at 7000 rpm for 3 min. The pellets were then disrupted in lysis buffer (50 mM Tris-HCl, pH 7.5, 2 mM EDTA, 100 mM NaCl, 1 x Nonidet P-40, supplemented with protease inhibitor (Sigma Aldrich)). The solubilized lysates were then centrifuged at 13,000 rpm for 5 min at 4 °C and supernatants were collected for further analysis. Equivalent amount of total protein (20-30 μg) were separated by SDS-polyacrylamide gel electrophoresis on 10% polyacrylamide gels and then transferred to polyvinylidene membranes. Membranes were blocked with 5% dry milk in PBS/0.1% (v/v) Tween 20 (PBST) for 1 h at room temperature. Membranes were then incubated with primary antibodies overnight at 4 °C in PBST. The membranes were then washed three times with PBST (10 min each time), incubated with the appropriate horseradish peroxidase-conjugated secondary antibody for 40 min at room temperature and followed by three times washes with PBST. Immunoreactive bands were then revealed by ECL solution, using standard X-ray film.

Assessment of proliferation

5 x 10⁴ cells were cultured in 96-well plates for 12 h, then incubated for 12 h with indicated concentrations of TP or vanadate. The cultures then were pulsed with 0.5 μCi/well [3H]-thymidine (Amersham, Buckinghamshire, UK) for 12 h, and harvested onto cellulose filters. The cellulose filters were placed in vials with 3 mL of scintillation liquid and read in a beta radiation counter (Beckman LS 6000SE, Fullerton, CA, USA). Results are expressed in percentages. The mean counts per minute obtained from the control cells were considered to be 100%.

Determination of LDH release

The release of LDH into the culture medium was regarded as an indicator of necrotic cellular damage and cytotoxicity. LDH is a stable cytoplasmic enzyme in all cells, and is rapidly released into the cell culture if the plasma membrane was damaged by oxidant, such as H₂O₂. An increase of LDH activity in the culture supernatant indicated an increase in the number of necrotic cell dead. Briefly, after immortalized HT22 cells were exposed to various concentrations of TP or 300 μM of H₂O₂ (as a positive control), the supernatant was collected for LDH determination in the cell-free medium. The cell pellet and the cells remaining on the well were lysed in 0.5 mL of lysis buffer (0.5% Triton X-100 in 50 mM Tris-HCl buffer, pH 7.5). The release of intracellular LDH to extracellular medium was measured by determining LDH activity and was expressed as the percentage of total LDH activity (total LDH activity = LDH activity in the cell-free medium + LDH activity in the cell medium). LDH released was calculated according to the following equation: LDH released (%) = (LDH activity in the cell-free medium/total LDH activity) x 100. LDH activity was measured with a commercial kit (Sigma Aldrich).

Statistical analysis

The results are presented as mean ± SE. Analysis of variance (ANOVA) followed by Tukey's post hoc test was performed to compare the mean values between various groups. Differences were considered statistically significant at p < 0.05.

RESULTS

Given that TP was previously identified as an inhibitor for MKP-1 expression, the effect of TP on MKP-1 expression in immortalized HT22 hippocampal cells was first analyzed by Western blot. As shown in Fig. 1, TP (0.5 μM) almost completely inhibited MKP-1 expression at 6 h, as compared with control cells not exposed to TP. The MKP-1 expression was confirmed by the positive and negative control cells transfected with MKP-1 siRNA (for blockage of MKP-1 cellular synthesis) or MKP-1 gene (for over-expression of MKP-1), respectively.

The effect of TP on the viability of HT22 cells was next examined after incubation in medium containing TP for 24 h. HT22 cells were incubated with H₂O₂, served as a positive control of necrosis, or with paclitaxel, an anti-cancer drug that is well known to inhibit cell growth.

**Fig. 1.** Effect of tritptide (TP) on the expression of mitogen-activated protein kinase phosphatase-1 (MKP-1) in immortalized HT22 cells. Cells were treated with indicated concentrations of TP for 6 h. The cells that were transiently transfected with either MKP-1 small interfering RNA (MKP-1 siRNA; Lane 5) or MKP-1 gene (Lane 6) served as the controls for MKP-1 expression, and were cultured for 6 h. Expression of MKP-1 was examined by Western blot analysis with anti-MKP-1 antibody, as described in materials and methods. Representative Western blots of three independent experiments are shown.
through induction of apoptosis\(^{17}\), served as a positive control of apoptosis. There was no significant change in the viability and the nuclei of HT22 cells (Fig. 2), as compared with control cells not exposed to TP2. In contrast, necrotic LDH release were observed in H\(_2\)O\(_2\)-treated cells (Fig. 2A). Condensed chromatin and fragmented nuclei were also found in paclitaxel-treated cells (Fig. 2B), which were classic characteristics of apoptotic cells. Although TP had no significant effect on the viability of HT22 cells for 24 h, this drug obviously inhibited cell growth even without cytotoxicity (Fig. 3). Interestingly, similar growth inhibition was also observed when the cells were transiently transfected with siRNA against MKP-1 (Fig. 3).

Treatment of HT22 cells with TP (0.5 \(\mu\)M) for 6 h resulted in ERK-1/2 phosphorylation (Fig. 4A). In contrast, TP had no significant effect on the phosphorylation of either p38 MAPK or JNK-1/2 (Fig. 4A). The same results were also observed when the cells were transiently transfected with MKP-1 siRNA (Fig. 4A). The time course of ERK-1/2 phosphorylation level showed that ERK-1/2 phosphorylation by TP was detected throughout the time course experiment up to 24 h (Fig. 4B). Similarly, the...
phosphatase inhibitor vanadate at 10 μM, which has been used extensively for the blockage of MKP-1 enzyme activity by other investigators,\textsuperscript{12,13,15} induced persistent ERK-1/2 phosphorylation (Fig. 5A) and reduced cell growth (Fig. 5B).

Finally, we investigated whether ERK-1/2 activation would involve in the inhibition of cell growth by TP, MKP-1 siRNA, and vanadate, using specific inhibitors for MAPKs. U0126, a specific ERK-1/2 inhibitor, completely inhibited the ERK-1/2 phosphorylation by TP, MKP-1 siRNA, and vanadate (Fig. 6A). When the cells were treated with U0126, the inhibitory effects of TP, MKP-1 siRNA, and vanadate on cell growth were also abolished (Fig. 6B). In contrast, a p38 MAPK inhibitor, SB203580, or a JNK-1/2 inhibitor, SP600125, had no effect on cell growth regardless of the presence or absence of TP, MKP-1 siRNA, or vanadate (not shown).

**DISCUSSION**

It is worthy to mention that TP can penetrate the blood-brain barrier easily because of its lipophilic character and small molecular size and may, thus, influence neuronal cells in the brain\textsuperscript{31}. On the basis of the results presented here, it is most likely that TP may be effective in controlling the abnormal proliferation of malignant cells, such as a brain tumor. In our study, immortalized HT22 hippocampal cells were used as *in vitro* malignant cells, because of their ability to continually proliferate under normal culture condition\textsuperscript{48}. Interestingly, MKP-1 is continually expressed during proliferation of HT22 cells\textsuperscript{30}. We previously found that the down-regulation of MKP-1 expression by MKP-1 siRNA had no significant effect on cell viability\textsuperscript{20}. The present study further confirmed that the blockage of MKP-1 expression by either MKP-1 siRNA or TP, an inhibitor
for MKP-1, had no effect on cell viability; neither apoptosis nor necrosis was found in our study. Instead, TP completely blocked MKP-1 expression and significantly inhibited cell growth. Moreover, the same effects could be also observed when the cellular synthesis of MKP-1 and its enzymatic activity were blocked by MKP-1 siRNA and a phosphatase inhibitor, respectively. These findings raised the possibility that there could be a close relationship between the down-regulation of MKP-1 expression and the inhibition of cell growth. In this regard, the present study examined whether the down-regulation of MKP-1 expression by TP would account for its antiproliferative activity in immortalized HT22 hippocampal cells.

Since MKP-1 down-regulates ERK-1/2 activity via dephosphorylation, we investigated whether the down-regulation of MKP-1 expression by TP could affect ERK-1/2 activation. Indeed, TP potentially induced ERK-1/2 phosphorylation, and the level of phosphorylated ERK-1/2 was sustained even for 24 h. This effect of TP on ERK-1/2 phosphorylation could be also mimicked by both MKP-1 siRNA and a phosphatase inhibitor, suggesting that the down-regulation of MKP-1 expression by TP could be responsible for the increased and persistent activation of ERK-1/2.

The rapid and transient activation of ERK-1/2 has been shown to correlate with the proliferative response. In contrast, delayed and persistent activation of ERK-1/2 has been reported to inhibit cellular proliferation. In our study, U0125, a specific inhibitor for ERK-1/2, abolished the inhibitory effects of TP on both ERK-1/2 phosphorylation and cell growth. Moreover, the antiproliferative effects of MKP-1 siRNA and a phosphatase inhibitor also abolished when ERK-1/2 phosphorylation was blocked by U0126. These findings suggest that the persistent activation of ERK-1/2 may account for the inhibition of cell growth by TP, MKP-1 siRNA, and vanadate. It should be noted that we could not detect the phosphorylation of p38 MAPK and JNK-1/2 during TP exposure until 6 h. Moreover, treatment with specific inhibitors of p38 MAPK and JNK-1/2 failed to block the antiproliferative effects of TP and MKP-1 siRNA, suggesting that p38 MAPK and JNK-1/2 may not be involved in the inhibition of cell growth by TP.

MKP-1 has been extensively studied in the context of regulating various physiological processes, including cellular proliferation, apoptosis, and inflammation. MKP-1 may function as a feedback control mechanism that governs cell growth and survival by limiting the activation of MAPKs. MKP-1 was found to be over-expressed in a number of human cancer tissues or immortalized cell lines, and this
may contribute to tumorigenesis. Interestingly, it has been reported that MKP-1-deficient fibroblasts exhibited reduced cell growth. It has also been reported that the inhibition of MKP-1 expression using siRNA technology or synthetic inhibitors led to persistent ERK-1/2 activity and significant blockage of cytokine-dependent proliferation of macrophages. In the light of these reports, it is most likely that TP at a non-cytotoxic dose can inhibit the proliferation of immortalized HT22 hippocampal cells via persistent activation of ERK-1/2 by suppressing MKP-1 expression.

CONCLUSION

The present study was undertaken to examine whether the down-regulation of MKP-1 expression by TP would account for its antiproliferative activity in HT22 hippocampal cells that were immortalized by viral oncogene. The data presented here suggest that TP at a non-cytotoxic dose inhibits cell growth via persistent activation of ERK-1/2 by inhibiting MKP-1 expression. Additionally, this study provides evidence that MKP-1 may play an important role in regulation of neuronal cell growth.

• Acknowledgements
This paper was supported by Wonkwang University in 2009.

References